Improving outcomes, cutting costs: Procuring NIA innovations via the NHS Innovation and Technology Tariff
Hosted by the NHS Innovation Accelerator (NIA), in partnership with local Academic Health Science Networks (AHSNs): Greater Manchester AHSN, the Innovation Agency, North East and North Cumbria AHSN, and Yorkshire & Humber AHSN.
When: Thursday 11 May, 4.00pm-6.00pm
Where: Clayton Hotel Leeds, Sweet Street, Leeds LS11 9AT
From 1 April 2017, NHS providers and commissioners can be reimbursed via NHS England for specified cost-saving, outcomes-based innovations.
This event offers the opportunity to learn more about the medtech devices and digital platforms available to procure via the new Innovation and Technology Tariff (ITT).
Why should I attend?
- Access some of the country’s best evidence-based innovations and be reimbursed by NHS England
- Meet the NIA Fellows who have developed these innovations and see first-hand how they work
- Learn how these innovations have improved efficiencies, benefitted patients and secured cost savings across other NHS organisations
- Find out how to replicate these benefits across your organisation
These innovations include:
- MyCOPD: Online self-management system for COPD proven to reduce acute hospital admissions (saving CCGs £370,000 per year), NHS spending, and improve the quality of patients’ lives.
- The Non-Injectable Arterial Connector (NIC): Patient safety device which stops medication being accidentally given through the arterial lines used to monitor the blood of patients in ICUs and operating theatres. Improves safety while offering regional savings of over £156,500 per year.
- PneuX Prevention System: Patient safety device designed to stop ventilator-associated pneumonia (VAP), affecting some 20,000 patients each year, around a third of whom will die, with each episode costing the NHS between £10,000 and £20,000.
- Episcissors-60: Guiding mediolateral episiotomy evidenced to minimise the risk of obstetric anal sphincter injury (OASIS), delivering savings through reduced litigation costs, elective caesarean sections and repair (£1,625 per patient).
- AliveCor’s Kardia: Mobile ECG device for the identification and measurement of atrial fibrillation (AF) – the cause of between 25,000-35,000 strokes in the UK per year.
- Urolift: Prostatic urethral lift systems to treat lower urinary tract symptoms of benign prostatic hyperplasia as a day case. The existing treatment pathway usually involves a hospital stay of three days.
This event includes presentations from NHS England with representation from your local Academic Health Science Networks (AHSNs): Greater Manchester AHSN, the Innovation Agency, North East and North Cumbria AHSN, and Yorkshire & Humber AHSN; plus opportunities for Q&A and access to further information and resources.
Spaces are limited, register to confirm your place here:
If you have any questions or would like additional information, please email Rebekah Tailor, NIA Communications and Engagement Manager: email@example.com